SE9703191L - Läkemedel för förbättring av muskelfunktionsdurationen eller behandling av muskelstörningar eller -sjukdom - Google Patents

Läkemedel för förbättring av muskelfunktionsdurationen eller behandling av muskelstörningar eller -sjukdom

Info

Publication number
SE9703191L
SE9703191L SE9703191A SE9703191A SE9703191L SE 9703191 L SE9703191 L SE 9703191L SE 9703191 A SE9703191 A SE 9703191A SE 9703191 A SE9703191 A SE 9703191A SE 9703191 L SE9703191 L SE 9703191L
Authority
SE
Sweden
Prior art keywords
treatment
muscle
drugs
disease
disorders
Prior art date
Application number
SE9703191A
Other languages
Unknown language ( )
English (en)
Other versions
SE9703191D0 (sv
SE512531C2 (sv
Inventor
Aake Lignell
Original Assignee
Astacarotene Ab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=20408142&utm_source=***_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SE9703191(L) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Astacarotene Ab filed Critical Astacarotene Ab
Priority to SE9703191A priority Critical patent/SE512531C2/sv
Publication of SE9703191D0 publication Critical patent/SE9703191D0/sv
Priority to AT98943128T priority patent/ATE230985T1/de
Priority to CA002299366A priority patent/CA2299366C/en
Priority to US09/485,704 priority patent/US6245818B1/en
Priority to DE69810784T priority patent/DE69810784T2/de
Priority to EP98943128A priority patent/EP1011653B1/en
Priority to JP2000508354A priority patent/JP3660244B2/ja
Priority to DK98943128T priority patent/DK1011653T3/da
Priority to PL98338982A priority patent/PL338982A1/xx
Priority to PCT/SE1998/001526 priority patent/WO1999011251A1/en
Priority to AU90989/98A priority patent/AU727349B2/en
Priority to ES98943128T priority patent/ES2191329T3/es
Publication of SE9703191L publication Critical patent/SE9703191L/sv
Priority to NO20001087A priority patent/NO20001087D0/no
Publication of SE512531C2 publication Critical patent/SE512531C2/sv

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/12—Ketones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Neurology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Steroid Compounds (AREA)
  • Fodder In General (AREA)
SE9703191A 1997-09-04 1997-09-04 Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur SE512531C2 (sv)

Priority Applications (13)

Application Number Priority Date Filing Date Title
SE9703191A SE512531C2 (sv) 1997-09-04 1997-09-04 Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur
AU90989/98A AU727349B2 (en) 1997-09-04 1998-08-26 Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases
ES98943128T ES2191329T3 (es) 1997-09-04 1998-08-26 Utilizacion de xantofilos en medicamentos para la mejora de la duracion de la funcion muscular o el tratamiento de trastornos o enfermedades musculares.
EP98943128A EP1011653B1 (en) 1997-09-04 1998-08-26 Use of xanthophylles in medicaments for improvement of duration of muscle function or treatment of muscle disorders or diseases
PL98338982A PL338982A1 (en) 1997-09-04 1998-08-26 Drug for improving duration of muscle action or for treating muscular disorders or diseases
US09/485,704 US6245818B1 (en) 1997-09-04 1998-08-26 Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases
DE69810784T DE69810784T2 (de) 1997-09-04 1998-08-26 Verwendung von xanthophyllen zur herstellung von arzneimitteln zur verbesserung der muskel-funktionsdauer oder zur behandlung von muskelstörungen oder erkrankungen
AT98943128T ATE230985T1 (de) 1997-09-04 1998-08-26 Verwendung von xanthophyllen zur herstellung von arzneimitteln zur verbesserung der muskel- funktionsdauer oder zur behandlung von muskelstörungen oder erkrankungen
JP2000508354A JP3660244B2 (ja) 1997-09-04 1998-08-26 筋肉機能の持続時間を改善し、または筋肉障害もしくは疾患を治療するための医薬品
DK98943128T DK1011653T3 (da) 1997-09-04 1998-08-26 Anvendelse af xanthophyller i medikamenter til forbedring af varigheden af muskelfunktion eller behandling af muskelforstyrrelser eller -lidelser
CA002299366A CA2299366C (en) 1997-09-04 1998-08-26 Use of xanthophylls for improvement of duration of muscle function or treatment of muscle disorders or diseases
PCT/SE1998/001526 WO1999011251A1 (en) 1997-09-04 1998-08-26 Medicament for improvement of duration of muscle function or treatment of muscle disorders or diseases
NO20001087A NO20001087D0 (no) 1997-09-04 2000-03-02 Medikament for forlengelse av muskelfunksjon eller behandling av muskelforstyrrelser eller -sykdommer

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
SE9703191A SE512531C2 (sv) 1997-09-04 1997-09-04 Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur

Publications (3)

Publication Number Publication Date
SE9703191D0 SE9703191D0 (sv) 1997-09-04
SE9703191L true SE9703191L (sv) 1999-03-05
SE512531C2 SE512531C2 (sv) 2000-03-27

Family

ID=20408142

Family Applications (1)

Application Number Title Priority Date Filing Date
SE9703191A SE512531C2 (sv) 1997-09-04 1997-09-04 Användning av åtminstone en typ av xantofyller för framställning av ett läkemedel för profylaktisk och/eller terapeutisk förbättring av muskelfunktionsdurationen hos däggdjur och/eller behandling av muskelstörningar eller - sjukdomar hos däggdjur

Country Status (13)

Country Link
US (1) US6245818B1 (sv)
EP (1) EP1011653B1 (sv)
JP (1) JP3660244B2 (sv)
AT (1) ATE230985T1 (sv)
AU (1) AU727349B2 (sv)
CA (1) CA2299366C (sv)
DE (1) DE69810784T2 (sv)
DK (1) DK1011653T3 (sv)
ES (1) ES2191329T3 (sv)
NO (1) NO20001087D0 (sv)
PL (1) PL338982A1 (sv)
SE (1) SE512531C2 (sv)
WO (1) WO1999011251A1 (sv)

Families Citing this family (33)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7078040B2 (en) 2000-03-27 2006-07-18 Fuji Chemical Industry Co., Ltd. Method of inhibiting the expression of inflammatory cytokines and chemokines
SE0001071D0 (sv) * 2000-03-27 2000-03-27 Astacarotene Ab Method of inhibiting the expression of inflammatory cytokines and chemokines
US6900324B2 (en) 2000-09-07 2005-05-31 Astrazeneca Ab Process for preparing a substituted imidazopyridine compound
SE0003186D0 (sv) * 2000-09-07 2000-09-07 Astrazeneca Ab New process
US7723327B2 (en) 2002-07-29 2010-05-25 Cardax Pharmaceuticals, Inc. Carotenoid ester analogs or derivatives for the inhibition and amelioration of liver disease
US20050059635A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid ester analogs or derivatives for controlling C-reactive protein levels
CN1708480B (zh) 2002-07-29 2010-12-15 卡达克斯药物公司 用于抑制和改善疾病的类胡萝卜素结构类似物
US20050004235A1 (en) * 2002-07-29 2005-01-06 Lockwood Samuel Fournier Carotenoid analogs or derivatives for the inhibition and amelioration of liver disease
US20050026874A1 (en) * 2002-07-29 2005-02-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for the inhibition and amelioration of liver disease
US7345091B2 (en) 2002-07-29 2008-03-18 Cardax Pharmaceuticals, Inc. Carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US7521584B2 (en) * 2002-07-29 2009-04-21 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of disease
US20050148517A1 (en) * 2002-07-29 2005-07-07 Lockwood Samuel F. Carotenoid ether analogs or derivatives for controlling connexin 43 expression
US20050049248A1 (en) * 2002-07-29 2005-03-03 Lockwood Samuel Fournier Carotenoid ether analogs or derivatives for controlling C-reactive protein levels
US7763649B2 (en) 2002-07-29 2010-07-27 Cardax Pharmaceuticals, Inc. Carotenoid analogs or derivatives for controlling connexin 43 expression
US7375133B2 (en) * 2002-07-29 2008-05-20 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ether analogs or derivatives for the inhibition and amelioration of disease
US20050143475A1 (en) * 2002-07-29 2005-06-30 Lockwood Samuel F. Carotenoid analogs or derivatives for the inhibition and amelioration of ischemic reperfusion injury
US20050059659A1 (en) * 2002-07-29 2005-03-17 Lockwood Samuel Fournier Carotenoid analogs or derivatives for controlling C-reactive protein levels
US7320997B2 (en) 2002-07-29 2008-01-22 Cardax Pharmaceuticals, Inc. Pharmaceutical compositions including carotenoid ester analogs or derivatives for the inhibition and amelioration of disease
WO2004021798A1 (es) * 2002-09-03 2004-03-18 Centro De Investigacion En Alimentacion Y Desarrollo A.C. Metodo de preparacion de microcapsulas de astaxantina en quitosano y producto obtenido
US8034372B2 (en) * 2003-03-05 2011-10-11 Nestec, Ltd. Dietary supplement for athletic pets
US7727752B2 (en) 2003-07-29 2010-06-01 Life Technologies Corporation Kinase and phosphatase assays
EP1682133A1 (en) * 2003-11-03 2006-07-26 AstraZeneca AB Imidazo 1,2-a pyridine derivatives for the treatment of silent gastro-esophageal reflux
SE0303451D0 (sv) * 2003-12-18 2003-12-18 Astrazeneca Ab New compounds
ES2587652T3 (es) * 2004-02-04 2016-10-26 Fuji Chemical Industry Co., Ltd. Astaxantina para mejorar la atrofia muscular
WO2005102356A1 (en) * 2004-04-14 2005-11-03 Hawaii Biotech, Inc. Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
US20060058269A1 (en) * 2004-04-14 2006-03-16 Lockwood Samuel F Carotenoid analogs or derivatives for the inhibition and amelioration of inflammation
WO2006039685A2 (en) 2004-10-01 2006-04-13 Hawaii Biotech, Inc. Methods for synthesis of chiral intermediates of carotenoids, carotenoid analogs, and carotenoid derivatives
JP5196708B2 (ja) * 2005-02-04 2013-05-15 富士化学工業株式会社 アスタキサンチン及び／又はそのエステルを有効成分とする筋萎縮改善剤及び飲食物
CA2610502A1 (en) 2005-03-29 2006-10-05 Cardax Pharmaceuticals, Inc. Reduction in complement activation and inflammation during tissue injury by carotenoids, carotenoid analogs, or derivatives thereof
US20090297492A1 (en) * 2008-05-30 2009-12-03 Yamaha Hatsudoki Kabushiki Kaisha Method for Improving Cognitive Performance
US10867701B1 (en) * 2010-06-28 2020-12-15 Heinrich Anhold System and method for optimizing patient-specific intervention strategies using point of care diagnostics
JP5924592B2 (ja) * 2013-04-30 2016-05-25 株式会社ダイセル 抗疲労用組成物
CN112057420A (zh) * 2020-09-21 2020-12-11 中国科学院烟台海岸带研究所 一种虾青素喷剂及其制备方法、使用方法

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2558372B1 (fr) * 1984-01-25 1987-08-07 Oreal Composition medicamenteuse pour le traitement de l'acne
JP2619491B2 (ja) * 1988-08-11 1997-06-11 サントリー株式会社 アスタキサンチン含有組成物
JPH0665033A (ja) * 1992-08-11 1994-03-08 Lion Corp 口腔用組成物
IL110139A0 (en) * 1993-06-28 1994-10-07 Howard Foundation Pharmaceutically-active antioxidants
WO1996023489A2 (de) * 1995-02-03 1996-08-08 Basf Aktiengesellschaft Verwendung von carotinoiden zur herstellung von arzneimitteln zur behandlung von dermatosen
JPH09124470A (ja) * 1995-10-26 1997-05-13 Suntory Ltd 抗ストレス組成物

Also Published As

Publication number Publication date
DK1011653T3 (da) 2003-05-26
AU727349B2 (en) 2000-12-14
ATE230985T1 (de) 2003-02-15
NO20001087L (no) 2000-03-02
DE69810784D1 (de) 2003-02-20
CA2299366A1 (en) 1999-03-11
US6245818B1 (en) 2001-06-12
DE69810784T2 (de) 2003-11-13
ES2191329T3 (es) 2003-09-01
CA2299366C (en) 2008-04-22
SE9703191D0 (sv) 1997-09-04
JP2001514215A (ja) 2001-09-11
AU9098998A (en) 1999-03-22
EP1011653A1 (en) 2000-06-28
EP1011653B1 (en) 2003-01-15
JP3660244B2 (ja) 2005-06-15
NO20001087D0 (no) 2000-03-02
SE512531C2 (sv) 2000-03-27
WO1999011251A1 (en) 1999-03-11
PL338982A1 (en) 2000-12-04

Similar Documents

Publication Publication Date Title
SE9703191L (sv) Läkemedel för förbättring av muskelfunktionsdurationen eller behandling av muskelstörningar eller -sjukdom
ATE515265T1 (de) Vitamin d und dessen analoge zur behandlung vom tumoren und anderen hyperproliferativen erkrankungen
ES2162615T3 (es) Metodo para tratar o prevenir diabetes de tipo 1 mediante la administracion oral de insulina.
DK0991479T3 (da) Pakningsenhed til indgivelse til lugteområdet
PT97552A (pt) Processo para a preparacao de formas de dosagem para administracao de farmacos para o tratamento da doenca de parkison
ATE234602T1 (de) Verabreichungsform zur abgabe von steigenden wirkstoffdosen
ATE306931T1 (de) Unterdrückung von veränderungen in zusammenhang mit beta-amyloid bei alzheimer
AU3040995A (en) Treatment of autoimmune diseases by oral administration of autoantigens
HK1031197A1 (en) Osmotic dosage form comprising first and second coats
BR9106114A (pt) Metodo para tratar ou prevenir uma doenca auto-imune (ad) e formulacao farmaceutica
IL104880A (en) Pharmaceutical composition comprising antigen for autoimmune diseases suppression
NO964864L (no) Orale, flytende alendronatpreparater
MY124853A (en) 4-amino-5-phenyl-7-cyclobutyl-pyrrolo[2,3-d]pyrimidine derivatives.
NO890186L (no) Fremgangsmaate for fremstilling av en avgivelses- og/ellerdoseringsform for legemiddelaktive stoffer.
BR9802537A (pt) Método para anestesiar um paciente humano antes de cirurgias de porte dose unitária e sistema farmacêutico para administração
DE3787477D1 (de) Nasal applizierbares Arzneimittel, Verfahren zu seiner Herstellung und seine Verwendung.
AR002724A1 (es) Peptido purificado fisiologicamente activo, sales de adicion de acido y sales de bases de dicho peptido, formas de dosificacion oral, intra-traqueal ynasal que comprenden a dicho peptido, formulacion farmaceutica que comprende a dicho peptido, usos de dicho peptido, metodo para la preparacion de dicha
AU3401093A (en) Therapeutic agent for threatened abortion
BG103905A (en) New bpc peptide salts with organoprotective activity, method for their preparation and application in medicine
EA199800770A1 (ru) Лекарственный препарат для терапевтического лечения вирусного гепатита
AR109456A2 (es) Uso de et743 para la preparación de un medicamento para el tratamiento de un paciente humano afectado por cáncer mediante terapia de combinación
WO1998036778A8 (en) Sustained drug delivery and compositions useful therefor
RU97116821A (ru) Способ лечения респираторных заболеваний
RU95102712A (ru) Липосомный фармацевтический препарат и лечебно-профилактический крем на его основе
RU97115801A (ru) Способ лечения стенозирующих ларинготрахеитов у детей

Legal Events

Date Code Title Description
NUG Patent has lapsed